US4790991A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Ingestible aggregate and delivery system prepared therefrom
Assignee: Warner Lambert Co LLC
•
Filing: 1988-02-29
•
Granted: 1988-12-13
•
Expires: 2008-02-29
Abstract
Abstract The present invention relates to an ingestible aggregate comprising a pre-swelled substantially anhydrous hydrocolloid and a substrate. More particularly this invention relates to an aggregate having as a substrate a dietary fiber and/or drug wherein the composition can be administered in a therapeutically effective amount. Hydrocolloids useful include natural and modified gums, celluloses, modified celluloses, pectins, mucillages, modified starches, noncellulose polysaccharides, algal polysaccharides and mixtures thereof. The aggregate should be in the size range of about 4 to about 70 U.S. mesh. The unpleasant taste and mouthfeel of the fiber and/or drug is effectively masked and substantial hydration is delayed until the compositions reaches the stomach. The compositions are substantially more palatable, devoid of graininess, bitterness or fibrous texture. The pleasant taste of the composition encourages patient compliance with their fiber or drug therapy.
Inventors
- 👤 James J. Shaw
- 👤 Shri C. Sharma
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 05:04
CPC Classifications
A; A23; A23G; A23G3/00; A23G3/34; A23G3/36; A23G3/364; A23G3/368; A23L; A23L33/00; A23L33/20; A23L33/21; A61; A61K; A61K9/00; A61K9/0012; A61K9/0053; A61K9/0056; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1652; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5036; A61K9/5042; A61K9/5047; A61K9/5073
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
84 words
A method for treating hypercholesterolemia and related disorders comprising administering to a patient in need of treatment of said condition a therapeutically effective amount of an ingestible aggregate composition comprising the aggregate particles produced by (a) preparing an aqueous composition of a hydrocolloid; (b) fluidizing substantially anhydrous substrate particles in an air stream; (c) contacting the substrate particle with the aqueous hydrocolloid composition to form the aggregates of the substrate and hydrocolloid; and (d) drying and collecting the aggregates, wherein the substrate contains cholestyramine.
Claim 2
Independent Claim
84 words
A method for treating hypercholesterolemia and related disorders comprising administering to a patient in need of treatment of said condition a therapeutically effective amount of an ingestible aggregate composition comprising the aggregate particles produced by (a) preparing an aqueous composition of a hydrocolloid; (b) fluidizing substantially anhydrous substrate particles in an air stream; (c) contacting the substrate particle with the aqueous hydrocolloid composition to form the aggregates of the substrate and hydrocolloid; and (d) drying and collecting the aggregates, wherein the substrate contains cholestyramine.
Claim 3
Independent Claim
90 words
A method for treating hypercholesterolemia and related disorders comprising administering to a patient in need of treatment of said condition a therapeutically effective amount of a delivery system comprising an edible matrix and an ingestible aggregate consisting essentially of a pre-swelled substantially anhydrous hydrocolloid and a substrate, wherein the hydrocolloid at least partially entraps and binds the substrate, the substrate being selected from the group consisting of dietary fibers, drugs and mixtures thereof, wherein the substrate and the hydrocolloid are not the identical material and wherein the substrate contains cholestyramine.
Claim 4
Independent Claim
90 words
A method for treating hypercholesterolemia and related disorders comprising administering to a patient in need of treatment of said condition a therapeutically effective amount of a delivery system comprising an edible matrix and an ingestible aggregate consisting essentially of a pre-swelled substantially anhydrous hydrocolloid and a substrate, wherein the hydrocolloid at least partially entraps and binds the substrate, the substrate being selected from the group consisting of dietary fibers, drugs and mixtures thereof, wherein the substrate and the hydrocolloid are not the identical material and wherein the substrate contains cholestyramine.
Claim 5
Dependent Claim
18 words
The method of claim 2 wherein the ratio of hydrocolloid to substrate is about 3:1 to about 20:1.
Claim 6
Dependent Claim
13 words
The method of claim 2 wherein the edible matrix is a confectionary composition.
Claim 7
Dependent Claim
25 words
The method of claim 4 wherein the edible matrix is present in amounts of about 50% to about 99.9% by weight of the delivery system.
Claim 8
Dependent Claim
30 words
The method of claim 2 wherein the hydrocolloid is selected from the group consisting of natural and modified gums, pectin mucillages, modified starches, noncellulosic polysaccharides, algal polysaccharides and mixtures thereof.
Claim 9
Dependent Claim
28 words
The method of claim 2 wherein the hydrocolloid is selected from the group consisting of carboxymethyl cellulose, methyl cellulose, karaya gum, sodium alginate, calcium alginate, and mixtures thereof.
Claim 10
Independent Claim
116 words
A method of treating mineral deficiencies comprising administering to a patient in need of treatment of said condition a therapeutically effective amount of an ingestible aggregate composition comprising aggregate particles, produced by (a) preparing an aqueous composition of a hydrocolloid; (b) fluidizing substantially anhydrous substrate particles in an air stream; (c) contacting the substrate particles with the aqueous hydrocolloid composition to form the aggregates of the substrate and hydrocolloid; and (d) drying and collecting the aggregates, of a drug and a hydrocolloid wherein the hydrocolloid at least partially entraps the drug, and wherein the substrate is at least one drug selected from the group consisting of pharmaceutically acceptable salts of alkali metal and alkaline earth metals.
Claim 11
Independent Claim
116 words
A method of treating mineral deficiencies comprising administering to a patient in need of treatment of said condition a therapeutically effective amount of an ingestible aggregate composition comprising aggregate particles, produced by (a) preparing an aqueous composition of a hydrocolloid; (b) fluidizing substantially anhydrous substrate particles in an air stream; (c) contacting the substrate particles with the aqueous hydrocolloid composition to form the aggregates of the substrate and hydrocolloid; and (d) drying and collecting the aggregates, of a drug and a hydrocolloid wherein the hydrocolloid at least partially entraps the drug, and wherein the substrate is at least one drug selected from the group consisting of pharmaceutically acceptable salts of alkali metal and alkaline earth metals.
Claim 12
Dependent Claim
24 words
The method of claim 8 wherein the salt is selected from the group consisting of potassium chloride, calcium carbonate, magnesium oxide and mixture thereof.
References Cited (Backward Citations)
GB490001A
Cited
US2441927A
Cited
US2444412A
Cited
GB929391A
Cited
US3308020A
Cited
US3383281A
Cited
US3499960A
Cited
GB1132233A
Cited
GB1181003A
Cited
GB1262556A
Cited
US3821414A
Cited
US3780171A
Cited
US3843819A
Cited
US3827899A
Cited
US3959472A
Cited
US3974272A
Cited
GB1446352A
Cited
US3907983A
Cited
US3914456A
Cited
US4041153A
Cited
US4064234A
Cited
US3970750A
Cited
US4140756A
Cited
US4143163A
Cited
DE2629773A1
Cited
US4172120A
Cited
US4357960A
Cited
GB1573487A
Cited
US4151270A
Cited
US4154814A
Cited
US4216237A
Cited
US4347261A
Cited
US4191812A
Cited
US4359537A
Cited
US4380590A
Cited
US4200695A
Cited
US4312956A
Cited
WO1980000658A1
Cited
US4340585A
Cited
US4195078A
Cited
US4233288A
Cited
GB2050828A
Cited
US4393145A
Cited
US4257816A
Cited
US4259323A
Cited
US4259315A
Cited
US4404346A
Cited
US4707376A
Cited
US4341807A
Cited
US4352791A
Cited
US4401682A
Cited
JPS5839608A
Cited
US4447461A
Cited
JPS59187744A
Cited
US4517179A
Cited
US4565702A
Cited
US4619831A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-12-13 | 1992-06-13 | 1992-12-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-12-13 | 1996-06-13 | 1996-12-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-12-13 | 2000-06-13 | 2000-12-13 | $7700.00 | Window Closed / Lapsed |